The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AXOGEN INC | COM | 05463X106 | 25,272 | 2,429,999 | SH | SOLE | 2,429,999 | 0 | 0 | ||
| CATALYST BIOSCIENCES INC | COM NEW | 14888D208 | 344 | 78,622 | SH | SOLE | 78,622 | 0 | 0 | ||
| ENDOLOGIX INC | COM NEW | 29266S304 | 89 | 125,747 | SH | SOLE | 125,747 | 0 | 0 | ||
| EYEPOINT PHARMACEUTICALS INC | COM | 30233G100 | 42,747 | 41,909,219 | SH | SOLE | 41,909,219 | 0 | 0 | ||
| MEDICINOVA INC | COM NEW | 58468P206 | 4,114 | 1,105,941 | SH | SOLE | 1,105,941 | 0 | 0 | ||
| REVANCE THERAPEUTICS INC | COM | 761330109 | 49,462 | 3,342,047 | SH | SOLE | 3,342,047 | 0 | 0 | ||
| TELA BIO, INC. | COM | 872381108 | 8,400 | 1,074,231 | SH | SOLE | 1,074,231 | 0 | 0 | ||
| VENUS CONCEPT, INC. | COM | 92332W105 | 24,913 | 7,017,856 | SH | SOLE | 7,017,856 | 0 | 0 | ||